I agree with that. I'm at about "slightly better" than 50/50 simply based on the endometrial results.
You mention the mucositis. It seems as though Ridaforolimus has more of this than the other mTORs, is that about right? I read a post one a single Ridaforolimus patient who was saying that his mouth sores were unbearable and it made the treatment not even worth it, fwiw. Of course, that was only one patient.
I can already hear The Harv now IF the trial fails.....Despite not meeting our endpoint, we are diligently working with our colleagues at Merck and data-mining the patient set as we believe there is evidence of the drug having clinical benefit response in a couple subsets of sarcoma. While we are not sure of why the endpoint was not met, whether it may be due to overwhelming response in the placebo group, rest assured, we and our colleagues at Merck are working hard to determine what happened. Rest assured, this is not the end of R as we have several other combination studies with Merck and Company. And we are at the strongest point in our history with P in the pivotal trial and we are still on track to becoming a fully integrated oncology company. We would like to thank all the patients, blah blah blah........
One last question of you ex (and all of the rest of you Araid maniacs, myself included):
If you had no current position in Ariad and was looking for a chance to push in a substantial wager. What presents a better opportunity for new money in Ariad post SUCCEED trial news?
- A Rida success where share price will prob bounce anywhere from let's guess $6-$8/share.
- Rida fails to meet the end points of the trial. Where share price will prob drop to anywhere from $2-$2.50/share.
I'm talking straight up share value and potential for appreciation. Just something I have wondered recently.
News 
Market Data 
Discover 
